← Atlas Theme · spans 1 topics
In dMMR cancers, checkpoint blockade is now approved instead of surgery.
Within two weeks the FDA approved adjuvant atezolizumab that halves recurrence risk in dMMR colon cancer and dostarlimab alone that spared seven in ten dMMR rectal patients surgery, radiation, and chemotherapy entirely.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
FDA Grants Accelerated Approval to Dostarlimab (Jemperli) for MSI-H/dMMR Rectal Cancer — Immunotherapy-First Organ Preservation Becomes a Labeled Paradigm Seven in ten dMMR rectal patients were spared surgery, radiation, and chemotherapy entirely on a PD-1 label, codifying immunotherapy-instead-of-surgery.
Science & Health
FDA Approves Tecentriq (Atezolizumab) + Chemotherapy for Stage III dMMR Colon Cancer — Disease-Free Survival HR 0.50 in ATOMIC Adjuvant checkpoint blockade halves recurrence risk in dMMR colon cancer, extending immunotherapy-first into the curative-intent setting.